These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

713 related items for PubMed ID: 11331213

  • 21. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
    [Abstract] [Full Text] [Related]

  • 22. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW, Liu RT, Tung SC, Chien WY, Lu YC, Chen CH, Kuo MC, Hsieh JR, Wang ST.
    J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
    [Abstract] [Full Text] [Related]

  • 25. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ, Wiersinga WM, Prummel MF.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [Abstract] [Full Text] [Related]

  • 26. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, Tsukamoto Y, Hamada N.
    Endocr J; 2011 Sep; 58(2):95-100. PubMed ID: 21206137
    [Abstract] [Full Text] [Related]

  • 27. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
    Komaki T, Sakata S, Nakamura S, Matsuda M, Kojima N, Takuno H, Miura K.
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul 20; 65(7):627-39. PubMed ID: 2583311
    [Abstract] [Full Text] [Related]

  • 28. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun 20; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 29. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
    Sjölin G, Holmberg M, Törring O, Byström K, Khamisi S, de Laval D, Abraham-Nordling M, Calissendorff J, Lantz M, Hallengren B, Filipsson Nyström H, Wallin G.
    Thyroid; 2019 Nov 20; 29(11):1545-1557. PubMed ID: 31482765
    [Abstract] [Full Text] [Related]

  • 30. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A.
    Thyroid; 2000 Oct 20; 10(10):891-6. PubMed ID: 11081255
    [Abstract] [Full Text] [Related]

  • 31. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
    Kuo SW, Huang WS, Hu CA, Liao WK, Fung TC, Wu SY.
    Eur J Endocrinol; 1994 Aug 20; 131(2):125-30. PubMed ID: 8075781
    [Abstract] [Full Text] [Related]

  • 32. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.
    Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, Cusini C, Sabatino J, Ippolito S, Piantanida E, Tanda ML, Chiovato L, Wiersinga WM, Bartalena L.
    J Endocrinol Invest; 2018 Dec 20; 41(12):1425-1432. PubMed ID: 29946800
    [Abstract] [Full Text] [Related]

  • 33. Evaluation of serum basal thyrotrophin levels and thyrotrophin receptor antibody activities as prognostic markers for discontinuation of antithyroid drug treatment in patients with Graves' disease.
    Cho BY, Shong MH, Yi KH, Lee HK, Koh CS, Min HK.
    Clin Endocrinol (Oxf); 1992 Jun 20; 36(6):585-90. PubMed ID: 1358483
    [Abstract] [Full Text] [Related]

  • 34. "Block-and-replace" treatment in Graves' disease: experience in a cohort of pediatric patients.
    Vigone MC, Peroni E, Di Frenna M, Mora S, Barera G, Weber G.
    J Endocrinol Invest; 2020 May 20; 43(5):595-600. PubMed ID: 31713721
    [Abstract] [Full Text] [Related]

  • 35. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S, Takata K, Arishima T, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Miyauchi A.
    Thyroid; 2008 Jan 20; 18(1):63-6. PubMed ID: 18302519
    [Abstract] [Full Text] [Related]

  • 36. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, Bucci I, Carpentieri M, Di Nenno B, Di Blasio A, Vitti P, Monaco F, Napolitano G.
    J Clin Endocrinol Metab; 2012 Jul 20; 97(7):E1080-7. PubMed ID: 22492869
    [Abstract] [Full Text] [Related]

  • 37. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
    Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience T.
    Clin Endocrinol (Oxf); 1997 Oct 20; 47(4):425-30. PubMed ID: 9404440
    [Abstract] [Full Text] [Related]

  • 38. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
    Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M, Sanmartí A.
    J Clin Endocrinol Metab; 1997 Aug 20; 82(8):2410-3. PubMed ID: 9253309
    [Abstract] [Full Text] [Related]

  • 39. Recent trends in the management of Graves' hyperthyroidism in Japan: opinion survey results, especially on the combination therapy of antithyroid drug and thyroid hormone.
    Mori T, Sugawa H, Kosugi S, Ueda M, Hai N, Matsuda A.
    Endocr J; 1997 Aug 20; 44(4):509-17. PubMed ID: 9447283
    [Abstract] [Full Text] [Related]

  • 40. Effects of thyroid status on thyroid autoimmunity expression in euthyroid and hypothyroid patients with Hashimoto's thyroiditis.
    Rieu M, Richard A, Rosilio M, Laplanche S, Ropion V, Fombeur JP, Berrod JL.
    Clin Endocrinol (Oxf); 1994 Apr 20; 40(4):529-35. PubMed ID: 8187321
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.